Literature DB >> 2004308

Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.

S O'Brien1, R Witt, M Talpaz, H Kantarjian.   

Abstract

Treatment of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) with recombinant interferon-alpha (IFN-A) results in complete disappearance of the Ph chromosome in about 10% to 15% of patients in early chronic phase. This group has a long survival and very low incidence of blast crisis. The first known case is reported of extramedullary blastic transformation in a patient with medullary complete cytogenetic response (0% Ph-positive metaphases) to IFN-A. Four episodes of extramedullary blast crisis have occurred in this patient. The first three episodes were lymphoid by morphology and cytochemical stains. Molecular analysis confirmed breakpoint cluster region rearrangement. The most recent transformation was myeloid in nature and involved bone and pulmonary parenchyma. The patient is currently undergoing a second autologous transplantation with stored bone marrow that is Ph negative. The patient has survived more than 18 months since the first episode of blast crisis, and the bone marrow is normal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004308     DOI: 10.1002/1097-0142(19910401)67:7<1946::aid-cncr2820670720>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Chronic Myeloid Leukemia with Extramedullary Blast Crisis: Two Unusual Sites with Review of Literature.

Authors:  Kamal Kant Sahu; Pankaj Malhotra; Preithy Uthamalingam; Gaurav Prakash; Amanjit Bal; Neelam Varma; Subhash Chandar Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-10-29       Impact factor: 0.900

2.  Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis.

Authors:  Akihiko Gotoh; Keisuke Miyazawa; Yoshiko Uchida; Goro Sashida; Ken Kawakubo; Yuzuru Kuriyama; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.